Compare · CELZ vs NU
CELZ vs NU
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Nu Holdings Ltd. (NU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and NU operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- NU is the larger of the two at $73.51B, about 8992.9x CELZ ($8.2M).
- Over the past year, CELZ is down 60.6% and NU is up 6.2% - NU leads by 66.8 points.
- NU has been more active in the news (16 items in the past 4 weeks vs 5 for CELZ).
- NU has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Creative Medical Technology Holdings Inc.
- Nu Holdings Ltd.
- Price
- $1.25+1.63%
- $15.13+2.61%
- Market cap
- $8.2M
- $73.51B
- 1M return
- +53.70%
- +4.09%
- 1Y return
- -60.60%
- +6.21%
- Industry
- Finance: Consumer Services
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 16
- Recent ratings
- 1
- 25
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Nu Holdings Ltd.
Nu Holdings Ltd. operates in the technology industry. The company was incorporated in 2016 and is based in Grand Cayman, Cayman Islands.
Latest CELZ
- Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
- SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.
- SEC Form S-3 filed by Creative Medical Technology Holdings Inc.
- SEC Form DEF 14A filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- SEC Form PRE 14A filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Issues Mid-Year Update
Latest NU
- US CEO & Chief Growth Officer Junqueira Cristina Helena Zingaretti sold $790,000 worth of Class A ordinary shares (50,000 units at $15.80) (SEC Form 4)
- Chief Risk Officer Fragelli Henrique Camossa Saldanha sold $3,505,232 worth of Class A ordinary shares (221,707 units at $15.81), decreasing direct ownership by 18% to 979,446 units (SEC Form 4)
- Nu Holdings Ltd. Reports Second Quarter 2026 Financial Results
- SEC Form 6-K filed by Nu Holdings Ltd.
- SEC Form 6-K filed by Nu Holdings Ltd.
- SEC Form 6-K filed by Nu Holdings Ltd.
- SEC Form 6-K filed by Nu Holdings Ltd.
- Director Marcus David was granted 25,290 units of Class A ordinary shares, increasing direct ownership by 4% to 655,039 units (SEC Form 4)
- Director Reses Jacqueline D was granted 27,096 units of Class A ordinary shares, increasing direct ownership by 145% to 45,754 units (SEC Form 4)
- Director Piacentini Diego was granted 23,483 units of Class A ordinary shares, increasing direct ownership by 313% to 30,986 units (SEC Form 4)